Articles with public access mandates - Marwan Fakih - US National Institutes of HealthLearn more
NoteFor this mandate, articles should be available from specific locations.
Not available based on mandate: 10
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ...
JCO Precision Oncology 3, 1-13, 2019
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors
MG Fakih, L Pendyala, W Brady, PF Smith, ME Ross, PJ Creaven, ...
Cancer chemotherapy and pharmacology 62, 499-508, 2008
315O sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase ib full expansion cohort
Y Kuboki, R Yaeger, MG Fakih, JH Strickler, T Masuishi, EJ Kim, ...
Annals of Oncology 33, S680-S681, 2022
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma
MG Fakih, K BullardDunn, GY Yang, L Pendyala, K Toth, C Andrews, ...
International Journal of Radiation Oncology* Biology* Physics 72 (3), 650-657, 2008
Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1, N 11 diethylnorspermine
S Hector, R Tummala, ND Kisiel, P Diegelman, S Vujcic, K Clark, M Fakih, ...
Cancer chemotherapy and pharmacology 62, 517-527, 2008
Phase Ib trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma
V Chung, P Frankel, D Lim, C Yeon, L Leong, J Chao, N Ruel, ...
Oncology 90 (6), 307-312, 2016
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
MW Saif, CR Becerra, MG Fakih, W Sun, L Popovic, S Krishnamurthi, ...
Cancer Chemotherapy and Pharmacology 88 (3), 485-497, 2021
P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or …
V Morris, K Guthrie, S Kopetz, R Breakstone, T Karasic, Z Hu, S Colby, ...
Annals of Oncology 34, S96, 2023
Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels
I Kurth, N Yamaguchi, C Andreu-Agullo, HS Tian, S Sridhar, S Takeda, ...
bioRxiv, 2021.04. 26.441371, 2021
Available based on mandate: 56
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ...
New England Journal of Medicine 383 (13), 1207-1217, 2020
Colon cancer
PF Engstrom, JP Arnoletti, AB Benson, YJ Chen, MA Choti, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 7 (8), 778-831, 2009
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ...
The Lancet Oncology 20 (4), 518-530, 2019
Geriatric assessment–driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial
D Li, CL Sun, H Kim, E Soto-Perez-de-Celis, V Chung, M Koczywas, ...
JAMA oncology 7 (11), e214158-e214158, 2021
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the …
E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, ...
Journal of clinical oncology 37 (17), 1460-1469, 2019
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ...
Journal of Clinical Oncology 27 (11), 1800-1805, 2009
Treatment of metastatic colorectal cancer: ASCO guideline
VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ...
Journal of Clinical Oncology 41 (3), 678-700, 2023
Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study
J Strosberg, N Mizuno, T Doi, E Grande, JP Delord, R Shapira-Frommer, ...
Clinical cancer research 26 (9), 2124-2130, 2020
Publication and funding information is determined automatically by a computer program